Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy

The need for effective cancer treatments continues to be a challenge for the biomedical research community. In this case, the advent of targeted therapy has significantly improved therapeutic outcomes. Drug discovery and development efforts targeting kinases have resulted in the approval of several...

Full description

Saved in:
Bibliographic Details
Published in:MedChemComm 2024-05, Vol.15 (5), p.1452-147
Main Authors: Halder, Pallabi, Rai, Anubhav, Talukdar, Vishal, Das, Parthasarathi, Lakkaniga, Naga Rajiv
Format: Article
Language:English
Subjects:
Antineoplastic drugs
Cancer therapies
Cores
Drug discovery
Inhibitors
Kinases
Medical research
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The need for effective cancer treatments continues to be a challenge for the biomedical research community. In this case, the advent of targeted therapy has significantly improved therapeutic outcomes. Drug discovery and development efforts targeting kinases have resulted in the approval of several small-molecule anti-cancer drugs based on ATP-mimicking heterocyclic cores. Pyrazolopyridines are a group of privileged heterocyclic cores in kinase drug discovery, which are present in several inhibitors that have been developed against various cancers. Notably, selpercatinib, glumetinib, camonsertib and olverembatinib have either received approval or are in late-phase clinical studies. This review presents the success stories employing pyrazolopyridine scaffolds as hinge-binding cores to address various challenges in kinase-targeted drug discovery research. Pyrazolopyridines have gained increasing attention in kinase-targeting anti-cancer drug discovery. This review analyzes the success stories wherein this bicycle was employed to address various challenges.
ISSN:2632-8682
2040-2503
2632-8682
2040-2511
DOI:10.1039/d4md00003j